Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02648-5
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Reviewers.","authors":"","doi":"10.1038/s41409-025-02648-5","DOIUrl":"https://doi.org/10.1038/s41409-025-02648-5","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"9-10"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02653-8
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group - Poster Sessions (NP001-NP106).","authors":"","doi":"10.1038/s41409-025-02653-8","DOIUrl":"https://doi.org/10.1038/s41409-025-02653-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"905-966"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02652-9
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group - Oral Session (NO001-NO028).","authors":"","doi":"10.1038/s41409-025-02652-9","DOIUrl":"https://doi.org/10.1038/s41409-025-02652-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"888-904"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02711-1
Radwan Massoud, Evgeny Klyuchnikov, Normann Steiner, Maroly Bohorquez Manjarres, Gaby Zeck, Rolf Krause, Silke Heidenreich, Claudia Langebrake, Adrin Dadkhah, Ina Rudolph, Rusudan Sabauri, Christian Niederwieser, Tetiana Perekhrestenko, Mirjam Reichard, Mathias Schäfersküpper, Franziska E. Marquard, Sofia Oechsler, Gunnar Weise, Kristin Rathje, Maraike Harfmann, Nico Gagelmann, Catherina Lück, Christine Wolschke, Francis Ayuk, Nicolaus Kröger
Myelodysplastic syndromes (MDS) can progress to AML and often require allogeneic hematopoietic stem cell transplantation (allo-SCT). The sequential FLAMSA-FB regimen, featuring a cytoreductive FLAMSA phase followed by fludarabine-busulfan (FB) conditioning, may enhance disease control. We retrospectively analyzed 106 untreated MDS patients with blasts 5–19% at the University Medical Center Hamburg who received either FLAMSA-FB (n = 45) or standard conditioning (n = 61: Thiotepa-Busulfan (n = 30), Fludarabine-Busulfan (n = 16), Treosulfan-Fludarabine (n = 15)). Median follow-up was 24 months. The FLAMSA group was younger (median age 56 vs. 62, p = 0.02), but baseline IPSS risk scores (p = 0.16) and donor types (p = 0.43) were comparable. Engraftment rates were similar. At two years, overall survival (OS) was 62% with FLAMSA and 68% with standard conditioning (p = 0.92), while progression-free survival (PFS) was 56% vs. 59% (p = 0.92). Non-relapse mortality (22% vs. 25%, p = 0.78) and cumulative incidence of relapse (22% vs. 13%, p = 0.12) did not differ significantly, nor did grade II–IV acute graft-versus-host disease (GVHD). Propensity score matching in 18 pairs confirmed no significant differences in OS, PFS, NRM, or CIR. However, moderate-to-severe chronic GVHD was higher with FLAMSA-FB (50% vs. 17%, p = 0.04). Thus, FLAMSA-FB did not improve transplant outcomes over standard conditioning but was linked to an increased risk of chronic GVHD.
{"title":"Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT","authors":"Radwan Massoud, Evgeny Klyuchnikov, Normann Steiner, Maroly Bohorquez Manjarres, Gaby Zeck, Rolf Krause, Silke Heidenreich, Claudia Langebrake, Adrin Dadkhah, Ina Rudolph, Rusudan Sabauri, Christian Niederwieser, Tetiana Perekhrestenko, Mirjam Reichard, Mathias Schäfersküpper, Franziska E. Marquard, Sofia Oechsler, Gunnar Weise, Kristin Rathje, Maraike Harfmann, Nico Gagelmann, Catherina Lück, Christine Wolschke, Francis Ayuk, Nicolaus Kröger","doi":"10.1038/s41409-025-02711-1","DOIUrl":"10.1038/s41409-025-02711-1","url":null,"abstract":"Myelodysplastic syndromes (MDS) can progress to AML and often require allogeneic hematopoietic stem cell transplantation (allo-SCT). The sequential FLAMSA-FB regimen, featuring a cytoreductive FLAMSA phase followed by fludarabine-busulfan (FB) conditioning, may enhance disease control. We retrospectively analyzed 106 untreated MDS patients with blasts 5–19% at the University Medical Center Hamburg who received either FLAMSA-FB (n = 45) or standard conditioning (n = 61: Thiotepa-Busulfan (n = 30), Fludarabine-Busulfan (n = 16), Treosulfan-Fludarabine (n = 15)). Median follow-up was 24 months. The FLAMSA group was younger (median age 56 vs. 62, p = 0.02), but baseline IPSS risk scores (p = 0.16) and donor types (p = 0.43) were comparable. Engraftment rates were similar. At two years, overall survival (OS) was 62% with FLAMSA and 68% with standard conditioning (p = 0.92), while progression-free survival (PFS) was 56% vs. 59% (p = 0.92). Non-relapse mortality (22% vs. 25%, p = 0.78) and cumulative incidence of relapse (22% vs. 13%, p = 0.12) did not differ significantly, nor did grade II–IV acute graft-versus-host disease (GVHD). Propensity score matching in 18 pairs confirmed no significant differences in OS, PFS, NRM, or CIR. However, moderate-to-severe chronic GVHD was higher with FLAMSA-FB (50% vs. 17%, p = 0.04). Thus, FLAMSA-FB did not improve transplant outcomes over standard conditioning but was linked to an increased risk of chronic GVHD.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 12","pages":"1642-1648"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-025-02711-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02696-x
Gandhi Damaj, Adèle de Masson, Peter Dreger, Ali Bazarbachi, Philipp Berning, Rafael F. Duarte, Christopher P. Fox, Emmanuella Guenova, Olivier Hermine, Charalampia Kyriakou, Alina Tanase, Olivier Tournilhac, Wojiech Jurczak, Imke E. Karsten, Stéphanie Nguyen Quoc, Yasmina Serroukh, Federico Stella, Gerald Wulf, Anna Sureda, Evangelia Papadavid, Pablo L. Ortiz-Romero, Annalisa Ruggeri, Isabel Sánchez-Ortega, Julia J. Scarisbrick, Ibrahim Yakoub-Agha, Francesco Onida, Norbert Schmitz
This manuscript provides expert recommendations on the role of allogeneic hematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides (MF) and Sezary Syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and hematologists. These recommendations aim to harmonise clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HCT early in the management of eligible patients with high-risk disease. Advanced stage, large-cell transformation, relapsed or refractory disease following systemic treatment, and N3-stage lymph node involvement are indicators that should trigger consultation with a transplant hematologist in parallel with a donor search. Early interaction between dermatologists and transplant hematologists is vital to avoiding delays, which can significantly impact post-transplant outcomes and survival.
{"title":"Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee","authors":"Gandhi Damaj, Adèle de Masson, Peter Dreger, Ali Bazarbachi, Philipp Berning, Rafael F. Duarte, Christopher P. Fox, Emmanuella Guenova, Olivier Hermine, Charalampia Kyriakou, Alina Tanase, Olivier Tournilhac, Wojiech Jurczak, Imke E. Karsten, Stéphanie Nguyen Quoc, Yasmina Serroukh, Federico Stella, Gerald Wulf, Anna Sureda, Evangelia Papadavid, Pablo L. Ortiz-Romero, Annalisa Ruggeri, Isabel Sánchez-Ortega, Julia J. Scarisbrick, Ibrahim Yakoub-Agha, Francesco Onida, Norbert Schmitz","doi":"10.1038/s41409-025-02696-x","DOIUrl":"10.1038/s41409-025-02696-x","url":null,"abstract":"This manuscript provides expert recommendations on the role of allogeneic hematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides (MF) and Sezary Syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and hematologists. These recommendations aim to harmonise clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HCT early in the management of eligible patients with high-risk disease. Advanced stage, large-cell transformation, relapsed or refractory disease following systemic treatment, and N3-stage lymph node involvement are indicators that should trigger consultation with a transplant hematologist in parallel with a donor search. Early interaction between dermatologists and transplant hematologists is vital to avoiding delays, which can significantly impact post-transplant outcomes and survival.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 12","pages":"1565-1573"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-025-02696-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02657-4
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group - Poster Session (P931-P942).","authors":"","doi":"10.1038/s41409-025-02657-4","DOIUrl":"https://doi.org/10.1038/s41409-025-02657-4","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"985-995"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02644-9
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Welcome Address.","authors":"","doi":"10.1038/s41409-025-02644-9","DOIUrl":"https://doi.org/10.1038/s41409-025-02644-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"1"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02659-2
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Quality Management Group - Poster Session (P943-P964).","authors":"","doi":"10.1038/s41409-025-02659-2","DOIUrl":"https://doi.org/10.1038/s41409-025-02659-2","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"998-1012"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02661-8
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy - Poster Session (P970-P982).","authors":"","doi":"10.1038/s41409-025-02661-8","DOIUrl":"https://doi.org/10.1038/s41409-025-02661-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"1017-1025"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02650-x
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Session (O008-O166).","authors":"","doi":"10.1038/s41409-025-02650-x","DOIUrl":"https://doi.org/10.1038/s41409-025-02650-x","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"19-182"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：